jections. Administration of estrogen after the first GnRH injection inhibited gonadotropin responses, whereas later estrogen therapy (after 1 d of GnRH pulses) blunted the GnRH induced FSH secretion without significantly impairing the LH response. In weight-regained anorexic patients who had spontaneous pulsatile LH secretion and a mean basal plasma estradiol concentration of 53±15 pg/ml, administration of GnRH pulses did not change plasma LH and a minimal FSH response was seen. The data indicate that the pattern of gonadotropin responses to low dose GnRH injections depends upon the degree of previous exposure of the pituitary to endogenous GnRH. Furthermore, estradiol selectively inhibits FSH secretion by a direct action on the pituitary gland. This action of estradiol provides an explanation for the selective reduction in FSH responses to GnRH seen during pubertal maturation in girls and during the mid-follicular stage of the menstrual cycle.
INTRODUCTION
Puberty is thought to result from increased secretion of gonadotropin-releasing hormone (GnRH)' by the hypothalamus with consequent increased secretion of pituitary gonadotropins and gonadal steroids. During this process, the pattern of pituitary responsiveness to GnRH changes. Results from both cross-sectional (1, 2) and longitudinal (3) studies in girls indicate that follicle-stimulating hormone (FSH) responses decrease and luteinizing hormone (LH) responses increase as maturation progresses. In an effort to elucidate the nature of these changing responses we have previously administered low doses of GnRH in a pulsatile manner, to mimic the presumed physiological pattern of GnRH secretion, to female patients with absent or greatly reduced endogenous GnRH secretion. Our results (4, 5) and those of others (6, 7) have shown that the initial response to GnRH is one of predominant FSH secretion that later declines, while LH responses gradually increase. This pattern seen over 5 d of pulsatile GnRH injections is similar to that present during sexual maturation in girls. Prolonged administration of GnRH pulses to GnRH-deficient females results in changes in plasma FSH and LH that closely resemble those seen during the follicular phase of the normal menstrual cycle (8, 9) . The initial rise in serum FSH declines after 4 or 5 d, when estradiol secretion from the developing follicle is increasing. This suggests that FSH secretion is selectively inhibited by estradiol.
To examine the factors governing gonadotropin responses in females, we have studied the effects of low dose GnRH pulses in patients with different hypothalamic-pituitary disorders or anorexia nervosa at low body weight. Girls with panhypopituitarism, isolated growth hormone deficiency, and isolated gonadotropin deficiency were studied in order to assess the effects of different degrees of previous exposure of the pituitary to endogenous GnRH. Although it is not possible to accurately determine the level of endogenous GnRH secretion in humans, panhypopituitary patients would be expected to have the most severe deficiency of GnRH; girls with isolated growth hormone deficiency should have GnRH On the following day (dky 0) 2 ml of normal saline was injected every 2 h through a heparin lock, 'to act as a control for the subsequent GnRH injections, and base-line plasma gonadotropins and gonadal steroids were measured. Plasma LH and FSH were determined in samples drawn every 20 min during the day (1200-1500 h) and during sleep (2400-0300 h). Plasma estradiol was measured in the 0800 and 1800 h samples. Starting on day 1, GnRH (0.025 gg/ kg) was injected every 2 h for 5 d. Plasma LH and FSH were measured in preinjection samples at 0800, 1000, 1200, 1600, 1800, 2400, and 0400 h, and estradiol in the 0800 and 1800 h samples. The acute gonadotropin respons'es to intravenous GnRH pulses were assessed by measurement of LH and FSH every 30 min after the 0800 and 1800 h injections. In patient 1 the acute gonadotropin response was also measured at 1200 h and in patients 3 and 4 acute responses were only measured at 0800 h due to blood volume restrictions.
Patients 1-8 and 14-18 were studied on the above protocol. The protocol was repeated on patients 2 and 5, after they had been taking micronized estradiol (Estrace) 0.5 or 1 mg b.i.d. for 2 and 1 mo, respectively. Estradiol was continued throughout the 5 d of GnRH injections. Patients 9 and 10 were started on micronized estradiol (2 mg loading dose at 1000 h followed by 1 mg b.i.d. at 1000 and 2200 h)
after the first intravenous injection of GnRH on day 1. Patients 11, 12, and 13 were started on the same estradiol regimen beginning at 1000 h on day 2 (after 24 h of intravenous GnRH injections).
Assays. Plasma GnRH, LH, FSH and estradiol were measured by previously reported radioimmunoassay (RIA) (10, (11) (12) (13) . Gonadotropin concentrations are reported as milliInternational Units of the second international reference preparation of human menopausal gonadotropin after conversion from LER 907, which was used as the assay standard. The limit of detectability of the estradiol assay depended upon the volume of plasma available and was 10-15 pg/ml when 2 ml were used, and 20-30 pg/ml when only 1 jections after which FSH rose to a mean of 5.3±0.3 on day 5 . In both patients, plasma estradiol remained below assay detectability throughout the study.
IGHD
Plasma hormone responses in the two prepubertal girls (patients 3 and 4) with IGHD are shown in Fig.  2 . Plasma LH responses were small in both patients and mean LH rose from 1.6±0.13 on day 0 to 4.4±0.65 mIU/ml on day 5 in patient 3, and from 2.7±0.11 to 4.0±0.25 mIU/ml in patient 4. In contrast to the panhypopituitary patients, both subjects with IGHD showed earlier responses in plasma FSH. In patient 3, mean FSH increased from 2.2±0.17 on day 0 to 3.7±0.67 mIU/ml on day 1 and then rose markedly to 27.3±1.4 mIU/ml on day 5. Plasma estradiol concentrations were at or below assay sensitivity until day 5 when estradiol (mean 32 pg/ml) was measurable in both samples. Patient 4 showed an immediate increase in plasma FSH after the first GnRH pulse and the mean FSH rose from 3.5±0.12 (day 0) to 6.1+0.71 mIU/ml on day 1. By day 2, FSH had risen to 8.2±0.7 and then plateaued through day 5 (10.1±0.51 mIU/ ml). Plasma estradiol was at or below the limit of detectability on day 0 and 1 but rose to 40 and 34 pg/ ml on days 3 and 4, respectively. The evening estradiol sample on day 5 was undetectable however, and the small plasma sample available did not allow repeat assay.
Effects of estrogen therapy on gonadotropin responses to GnRH pulses in GnRHdeficient patients Preceding estrogen therapy. Two patients, one with IGD (patient 5) and one with PHP (patient 2), were studied both before and during therapy with Estrace and hormone responses are shown in Fig. 3 . In patient 5, the immediate increase in plasma FSH seen during the initial study was completely abolished by estrogen therapy. In patient 2 FSH was undetectable throughout and the small FSH increase seen during the initial study did not occur. In contrast, plasma LH responses were reduced to a lesser degree by estrogen treatment and were not significantly lower on days 4 Effects of pulsatile GnRH injections in anorexia nervosa patients after weight regain Previous studies (16) (17) (18) (19) have shown that LH is secreted in a pulsatile manner, responsiveness to GnRH matures, and plasma estradiol concentrations increase, following weight regain in patients with anorexia nervosa. We therefore administered GnRH to five patients who had regained weight, but who remained amenorrhic, in an effort to determine the effects of increased endogenous estrogen concentrations on gonadotropin responses. The individual hormone concentrations are shown for patient 14 in Fig. 5 , and mean data for patients [14] [15] [16] [17] [18] are shown in Fig. 6 . All five patients showed evidence of pulsatile LH secretion on day 0, indicating the presence of endogenous GnRH secretion. The amplitude of the measured LH pulses on day 0 was 7.3±2.2 mIU/ml, which is similar magnitude to spontaneous LH pulses in normal women during the follicular stage of the cycle (unpublished observations) and to the LH increments in response to GnRH pulses (8.5±1.9 mIU/ml on day 5). Plasma estradiol levels on day 0 were 53±15 pg/ml. After injection of GnRH, no significant changes in mean plasma LH In all these studies, the concentrations of estradiol achieved also tended to reduce LH responses to GnRH, though the effect was much less marked than that on FSH secretion. Estradiol concentrations in the range of 40 to 100 pg/ml appear to inhibit both FSH and LH responses to GnRH and no augmentation of LH responsiveness to repetitive GnRH stimuli were noted. This observation is in agreement with previous studies of the effects of estradiol concentrations on LH secretion and the "self-priming" effect of GnRH. Estrogen induced positive-feedback was not evident in adult females unless plasma estradiol exceeded 300 pg/ml (23) . Similarly, augmented LH responses to GnRH normally occur after estradiol administration (24) or when estradiol is elevated in excess of 200 pg/ml during the menstrual cycle (25) .
These observations provide an explanation for the changing patterns of gonadotropin responses after prolonged low dose GnRH administration to GnRH-deficient females. Plasma hormone profiles closely resemble those seen during the follicular phase of the normal menstrual cycle (8, 9, 26) with an initial predominance of FSH that later declines when estradiol levels increase to a range of 50 to 100 pg/ml (9) . LH augmentation does not occur until estradiol has risen to concentrations of 200 pg/ml or higher. A selective feedback of estradiol on FSH may have important implications for the normal control of menstrual cycles. The FSH rise during the early follicular phase results in induction of LH receptors and aromatase activity in the maturing follicular (27, 28) and is essential for normal follicular development. Failure of FSH secretion results in inadequate follicular development and an ovulation, and reduced FSH secretion has been associated with a short luteal phase (29) . While this initial FSH secretion is essential for normal menstrual cyclicity, the temporary nature of the FSH predominance may also be important. Administration of preovulatory levels of estradiol to rhesus monkeys in the early follicular phase, leads to inhibition of FSH and prolongation of the follicular stage of the cycle (30) . In a normal cycle, the majority of the follicular phase estradiol increase appears to be secreted by the dominant follicle, as ablation of that follicle in monkeys results in an acute fall in estradiol (31) . Thus, increasing estradiol secretion from the dominant follicle would inhibit FSH secretion and the fall in FSH may be part of the mechanisms involved in inhibiting growth of other developing follicles. Growth of the dominant follicle may not be impaired by this reduction in FSH, as it has an increased blood supply (32) , and a high estradiol milieu that is known to augment ovarian responsiveness to gonadotropins (33 The results in amenorrheic patients after weight regain are also of interest. In these patients, pulsatile GnRH secretion was present as evidenced by spontaneous LH peaks and the administration of exogenous GnRH did not significantly change plasma LH and had minimal effects on FSH. In patients with an intact hypothalamic-pituitary-ovarian axis, the exact level of estradiol feedback (either hypothalamic or pituitary) cannot be determined. However, by analogy to the GnRH-deficient patients, the minimal rise in FSH was probably due to the preexisting plasma estradiol concentrations of 53 pg/ml exerting selective feedback on the pituitary. This has important implications for the use of pulsatile GnRH to induce ovulation in patients with hypothalamic amenorrhea. In previous studies GnRH administration has resulted in variable success in these patients (26, 34, 35 ) and short luteal phases have been reported. Numerous factors may contribute to the relatively poor results, and in some studies GnRH injections were not given in an appropriate dosage or in the pulsatile manner necessary for optimal gonadotropin responsiveness (36) . However, our results suggest that pulsatile GnRH may only be fully effective in patients with low basal estradiol concentrations, so that the initial response is one of predominant FSH secretion.
In conclusion, our data indicate that the pattern of gonadotropin responses to pulsatile GnRH is dependent upon the degree of previous exposure of the pituitary to endogenous gonadotropin-releasing hormone. In gonadotropin-deficient patients, the rapidity of the initial FSH response is related to the amount and/or duration of earlier GnRH secretion, and similarly the ovarian response is more rapid in patients who have previously been exposed to GnRH. Estradiol exerts a direct feedback on the pituitary to selectively inhibit FSH secretion. This action explains the diminishing FSH secretion seen during sexual maturation and may also be an important mechanism in the control of normal menstrual cycles.
